The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH

Size: px
Start display at page:

Download "The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH"

Transcription

1 HA Convention May 2015 The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH Division of Cardiology Department of Medicine Queen Elizabeth Hospital Kowloon Central Cluster Cecilia MC Chan 1, Michael KY Lee 1, CB Lam 1, C Leung 1, LK Chan 1, KC Chan 1, SF Chui 1, CY Wong 1, KT Chan 1 CS Chiang 1, MY Fan 1, KW Leung 1, HL Cheung 2, V Ng 2, E So 3, D Fok 3, MK Chan 4, W Chan 4, SF Yip 4, A Cheung 4 Department of Medicine 1 Department of Cardiothoracic Surgery 2 Department of Anaesthesiology 3 Department of Diagnostic Radiology & Imaging 4

2 Introduction Aortic Stenosis most common valvular heart disease in the elderly 4.6% in adults 75 years of age Healthy Aortic Valve Stenosed Aortic Valve

3

4 AVR Not performed in Some Patients with severe aortic stenosis if High surgical risk Short life expectancy Co-morbidities hindering GA, e.g. poor lung reserve Advanced age High frailty score Untreated Severe Aortic Stenosis Patients are at a High Risk for Death and a Poor Quality of Life repeated admission for symptom exacerbation

5 TAVI TAVI emerges as a viable alternative in inoperable or high risk elderly patients with symptomatic AS CoreValve Edwards Sapien Schoenhagen P et al. Eur Heart J 2009;30:

6 CoreValve Transcatheter Procedure Balloon catheter threaded through sheath and into heart CoreValve in place, procedure completed CoreValve placed into position over the diseased aortic valve Experimental Device in the United States and Limited by Federal Law to Investigational Use.

7 Key to Success Patient Selection - Understand our patients - Meticulous patient assessment Multi-disciplinary TAVI Heart Team - Collaborative effort

8 Understanding Our Patients Comorbidities Quality of life Frailty Advanced age Disability Expectations Motivations

9 Consenting for Risks and Benefits Mortality Myocardial Infarction Stroke Bleeding Acute Kidney Injury Vascular Complications Conduction Disturbances Valvular Function

10 Multi-disciplinary TAVI Heart Team Cardiac Anesthesiolgists Radiologists Interventional Cardiologists Patients with Severe AS TAVI Nurse Coordinator Echo Cardiologist Cardiac surgeons

11 TAVI Nurse Coordinator s Duties Pre-operative Preparation Patient and family s education Cardiologists assessment Echocardiogram Independent assessment by cardiac surgeon Coronary angiogram + Peripheral angiogram CT aortogram TAVI Heart Team meeting

12 TAVI Nurse Coordinator s Duties Follow-up & Data collection Arrange FU 1 week, 1 month and then every 3-4 months Drug compliance checking: - Plavix for 3 months, Aspirin for life Echo at 1, 6, 12 months and then yearly 6 min walk test at 1, 6, 12 months SF-12 at 3 & 12 months NYHA functional class assessment Risk factors control

13 TAVI Nurse Coordinator s Duties Assist Patient s Assessment Diagnostic Work-Up Coordination Patient and Family Education Communicate among Heart Team Members Development of Program Forms Waitlist Management Communication With Referral Base Data Collection HA TAVI Audit Follow-Up Program Support for Research Clinical Coordination & Education Convenor Role General Admin & Data Mx

14 The Hong Kong Experience First TAVI performed at Queen Elizabeth Hospital on Dec 6 th, 2010 Medtronic CoreValve - 86 Center # of Cases Queen Elizabeth Hospital 49 Prince of Wales Hospital 26 Queen Mary Hospital 15 HK Adventist Hospital 10 Union Hospital 1 TOTAL 101 Edwards Sapien - 15

15 2-Year All-cause Mortality US CoreValve Pivotal Trial Vs QEH ACC 2015 QEH TAVI 14.3% 14.3% 19

16 30-Day Stroke Rate 20.0% 15.0% 10.0% 9.6% 5.0% 0.0% 4.5% 4.0% 4.0% 1.9% 2.5% 1.7% 1.8% 0.0% 18 Fr S&E 1 ANZ 2 French 3 Belgian 4 German 5 UK 6 Italian 8 Asia QEH 1. Medtronic. Data on file. COR : 18 Fr Safety & Efficacy Study Re-Analysis, August 14, Meredith. VARC-adjudicated Outcomes in Inoperable and High Risk AS Patients. TCT 2010, Washington, DC. 3. Eltchaninoff. French Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 4. Bosmans. Belgian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 5. Zahn. German Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 6. Ludman. UK Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France. 7. Petronio. Italian Registry, TAVI Facts, Figures and National Registries. EuroPCR 2010, Paris, France.

17 Mean Gradient & Valve Area QEH Registry Mean Gradient (mmhg) MPG AVA AVA (cm 2 ) 0 Baseline 30 days 6 months 1 year 2 years 3 years 0 The PARTNER Trial CoreValve ADVANCE Study

18 QEH Symptom Status (NYHA Class) 100% NYHA Classification Changes in NYHA Classification 80% 35% 59% 60% 86% 40% 55% Class I Improved 2 Classes 20% 35% Class II Class III Improved 1 Class Maintained 0% 10% 14% 6% Pre-TAVI Post-TAVI 30-day Post-TAVI 6-month Class IV * NYHA: New York Heart Association Functional Classification for Heart Failure Stages (Class I = Best, Class IV = Worst)

19 6-Minute Walk Test Meters Pre-TAVI Paired-sample t-test: p<0.05 Post-TAVI

20 Measurement for Quality of Life (SF-12) Physical Component Pre-TAVI Post-TAVI Mental Component Score Physical Component Paired-sample t-test: p<0.05 Mental Component Paired-sample t-test: p<0.05

21 Conclusions Queen Elizabeth Hospital is the first hospital to perform TAVI in Hong Kong and adopt TAVI coordinator TAVI Nurse coordinator enhances the process of care and clinical triage coordination Pivotal role of TAVI Nurse coordinator as the central hub for the smoother logistics of the TAVI program

22 TAVI 3-Year Celebration

23

Transcatheter Aortic Valve Implantation (TAVI)

Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) QEH Registry A Multidisciplinary Team Approach Michael KY Lee 1, LK Chan 1, KC Chan 1, KT Chan 1, SF Chui 1, HS Ma 1, CY Wong 1, CS Chiang 1, P Li 1, CB Lam

More information

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong 3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease

More information

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013

More information

Transcatheter Aortic Valve Implantation (TAVI) The Time Has Come

Transcatheter Aortic Valve Implantation (TAVI) The Time Has Come Transcatheter Aortic Valve Implantation (TAVI) The Time Has Come Michael KY Lee 1, LK Chan 1, KC Chan 1, KT Chan 1, CS Chiang 1, P Li 1, CB Lam 1, C Leung 1, MC Chan 1,MY Fan 1, KW Leung 1, HL Cheung 2,

More information

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular

More information

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences

More information

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of

More information

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience The LGH TAVR Program James E. Harvey, MD, MSc Medical Director, Structural Heart Intervention The Heart Group of Lancaster

More information

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis

More information

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study 30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL

More information

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,

More information

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research

More information

The Role of TAVI in high-risk and normal-risk Patients

The Role of TAVI in high-risk and normal-risk Patients The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center

More information

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

More information

Disclosures. During the past 12 months, I have received research grants, advisory boards, consultation fees/honoraria, and/or travel expenses from:

Disclosures. During the past 12 months, I have received research grants, advisory boards, consultation fees/honoraria, and/or travel expenses from: Update on Transcatheter Aortic Valve Replacement Vinod H. Thourani, MD Associate Professor of Cardiothoracic Surgery Associate Director, Structural Heart Center Associate Director, CTS Clinical Research

More information

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000

More information

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ

More information

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of

More information

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant

More information

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder

More information

Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic

Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic Clinical & Practical Aspects of Establishing a Successful Heart & Valve Clinic Marci S. Damiano, RN, MSN Coordinator of the Center for Valvular Heart Disease Division of Cardiology, Department of Medicine

More information

Results of Transfemoral Transcatheter Aortic Valve Implantation

Results of Transfemoral Transcatheter Aortic Valve Implantation Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of

More information

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio

More information

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional

More information

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40 Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human

More information

Indication, Timing, Assessment and Update on TAVI

Indication, Timing, Assessment and Update on TAVI Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical

More information

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2. Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about

More information

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND

More information

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant

More information

Transcatheter Valve Replacement: Current State in 2017

Transcatheter Valve Replacement: Current State in 2017 Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP

More information

TAVR and Cardiac Surgeons

TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons Ragheb Hasan Consultant and Clinical Lead Cardiothoracic Surgeon Manchester Royal Infirmary, Oxford Road, Manchester UK Aortic Stenosis Is A Growing

More information

AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO

AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Potential conflicts of interest

More information

Aortic valve implantation using the femoral and apical access: a single center experience.

Aortic valve implantation using the femoral and apical access: a single center experience. Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany

More information

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More? CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology

More information

Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis

Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis James Bartholomew McClurken, MD FACC, FCCP, FACS, FESC Professor & Vice-Chair of Surgery, Temple University Hosp.,

More information

Post-TAVI Cerebral Embolisms and Potential Protection Means

Post-TAVI Cerebral Embolisms and Potential Protection Means Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest

More information

TAVI After PARTNER-2 : The Hamilton Approach

TAVI After PARTNER-2 : The Hamilton Approach TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University

More information

TAVR: Intermediate Risk Patients

TAVR: Intermediate Risk Patients TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University

More information

TAVR in 2020: What is Next!!!!

TAVR in 2020: What is Next!!!! TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures

More information

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National

More information

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives Transcatheter Aortic Valve Implantation Anaesthetic Prespectives Dr Simon Chan Consultant Department of Anaesthesia and Intensive Care Prince of Wales Hospital Hong Kong 11 Oct 2014 Aortic Stenosis Prevalence

More information

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist

More information

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Transcatheter Aortic Valve Implantation Present Status and Perspectives

Transcatheter Aortic Valve Implantation Present Status and Perspectives Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the

More information

TAVR IN INTERMEDIATE-RISK PATIENTS

TAVR IN INTERMEDIATE-RISK PATIENTS TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS

More information

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50

More information

TAVI in Korea, How to Avoid Conduction

TAVI in Korea, How to Avoid Conduction TAVI in Korea, How to Avoid Conduction Disturbance after CoreValve Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul,

More information

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine

More information

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial

More information

Transcatheter aortic valve implantation and pre-procedural risk assesment

Transcatheter aortic valve implantation and pre-procedural risk assesment Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who

More information

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division

More information

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,

More information

Emergency TAVI: Does It Exist? Is the Risk Higher?

Emergency TAVI: Does It Exist? Is the Risk Higher? Emergency TAVI: Does It Exist? Is the Risk Higher? Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 12 October 2014 Disclosure Statement of

More information

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa

More information

Aortic Stenosis: Background

Aortic Stenosis: Background Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic

More information

For the SURTAVI Investigators

For the SURTAVI Investigators Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter

More information

Policy Specific Section: March 30, 2012 March 7, 2013

Policy Specific Section: March 30, 2012 March 7, 2013 Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:

More information

Le TAVI pour tout le monde?

Le TAVI pour tout le monde? Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or

More information

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai

More information

1-YEAR OUTCOMES FROM JOHN WEBB, MD

1-YEAR OUTCOMES FROM JOHN WEBB, MD 1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following

More information

Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011

Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011 Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011 Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization(s)

More information

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,

More information

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential

More information

Transcatheter Aortic Valve Implantation (TAVI) Overview for Wales. Dr Richard Anderson University Hospital of Wales, Cardiff, UK

Transcatheter Aortic Valve Implantation (TAVI) Overview for Wales. Dr Richard Anderson University Hospital of Wales, Cardiff, UK Transcatheter Aortic Valve Implantation (TAVI) Overview for Wales Dr Richard Anderson University Hospital of Wales, Cardiff, UK Aortic stenosis is a disease of old age Age demographics in Wales % Wales

More information

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II

More information

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of

More information

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in

More information

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat

More information

The SAPIEN 3 TAVI Advantage

The SAPIEN 3 TAVI Advantage Edwards SAPIEN 3 Valve The SAPIEN 3 TAVI Advantage... The SAPIEN 3 TAVI Advantage The clear choice for your patients and your TAVI program Advanced valve and system designed to simplify procedures Consistent

More information

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate

More information

Centers for Medicare and Medicaid Services. National Coverage of Transcatheter Valve Technologies December 2015

Centers for Medicare and Medicaid Services. National Coverage of Transcatheter Valve Technologies December 2015 Centers for Medicare and Medicaid Services National Coverage of Transcatheter Valve Technologies December 2015 National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR) (20.32)

More information

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline

More information

TAVI: Nouveaux Horizons

TAVI: Nouveaux Horizons TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La

More information

Tissue vs Mechanical What s the Data??

Tissue vs Mechanical What s the Data?? Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William

More information

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,

More information

Transcatheter Aortic Valve Replacement with Evolut-R

Transcatheter Aortic Valve Replacement with Evolut-R Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures

More information

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II Department of Medicine Director, Transcatheter Aortic Valve Program June 2013 [First Name] [Last Name], [Suffix] [Hospital or Practice Name] [Address] [City], [State] [Zip] Dear Dr. [Last name], We are

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation

More information

Trans Catheter Aortic Valve Replacement

Trans Catheter Aortic Valve Replacement Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will

More information

Masterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach

Masterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach Masterclass III Advances in cardiac intervention Percutaneous valvular intervention a novel approach Professor Roger Boyle CBE National Director for Heart Disease and Stroke London Medical therapy Medical

More information

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R

More information

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences

More information

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium Medium Term Survival and Functional Status in Patients with Severe Aortic Stenosis Treated by Transcatheter Aortic Valvular Implantation in the PARTNER EU Trial Bernard De Bruyne, MD, PhD Cardiovascular

More information

Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization

Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization + K Spargias, MD, PhD THV Director Hygeia Hospital Disclosures - Proctor

More information

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Transcatheter Aortic-Valve Implantation for Aortic Stenosis Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues

Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues ETMIS 2012 ; Vol. 8 : N 0 8 Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues May 2012 A production of the Institut national d excellence

More information

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES

More information

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Transcatheter Aortic-Valve Implantation for Aortic Stenosis Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

2/4/2019. Nursing Perspective of TAVR. Disclosure. Learning Outcomes

2/4/2019. Nursing Perspective of TAVR. Disclosure. Learning Outcomes Nursing Perspective of TAVR Tara Whitmire, DNP, APRN-NP, NP-C, CHFN Nebraska Methodist Hospital Cardiothoracic Surgery Nurse Practitioner Danelle Homeyer, RN Methodist Physicians Clinic Director, Structural

More information

Surgery: The Gold Standard treatment for Aortic Stenosis

Surgery: The Gold Standard treatment for Aortic Stenosis Surgery: The Gold Standard treatment for Aortic Stenosis Andrew Chukwuemeka MD FRCS Consultant Cardiothoracic Surgeon Hammersmith Hospital, Imperial College Healthcare NHS Trust Hon. Senior Lecturer, National

More information

TAVR Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory. Cleveland Clinic.

TAVR Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory. Cleveland Clinic. TAVR 2015 Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Outline Aortic Stenosis TAVR Who should be considered for TAVR What are the treatment options? Valves, Approaches

More information

Transcatheter aortic valve implantation for aortic stenosis

Transcatheter aortic valve implantation for aortic stenosis NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs when the aortic valve

More information

Current Evidence in TAVI patients using ACURATE and LOTUS valves

Current Evidence in TAVI patients using ACURATE and LOTUS valves Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts

More information

Are Heart Valve Referral Centers Feasible in Latin America?

Are Heart Valve Referral Centers Feasible in Latin America? Are Heart Valve Referral Centers Feasible in Latin America? Vadim Kotowicz, MD Chief of Cardiovascular Surgery Department Italian Hospital of Buenos Aires Disclosure Medtronic inc. Consultanting Johnson

More information

TAVR: Review of the Robust Data from Randomized Trials

TAVR: Review of the Robust Data from Randomized Trials TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart

More information

IPAC date: May of 13

IPAC date: May of 13 National Institute for Health and Care Excellence IP685/3 Transcatheter aortic valve implantation (transcatheter aortic valve replacement) for aortic stenosis Consultation Comments table IPAC date: May

More information

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries

More information

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators 30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential

More information